Evidence map›Paper›PMID 27375374›Full record

ArticleAdvanced functional materials2016

Chitosan-Alginate Microcapsules Provide Gastric Protection and Intestinal Release of ICAM-1-Targeting Nanocarriers, Enabling GI Targeting In Vivo.

Rasa Ghaffarian, Edgar Pérez Herrero, Hyuntaek Oh, Srinivasa R Raghavan, Silvia Muro

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced functional materials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 122 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Mucoadhesive carriers for oral drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2022
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Intertwined mechanisms define transport of anti-ICAM nanocarriers across the endothelium and brain delivery of a therapeutic enzyme.Journal of controlled release : official journal of the Controlled Release Society · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Rasa GhaffarianFischell Department of Bioengineering, 2330 Jeong H. Kim Engineering Building, University of Maryland, College Park, MD 20742, USA.
Edgar Pérez HerreroInstitute for Bioscience and Biotechnology Research, 5115 Plant Sciences Building, University of Maryland, College Park, MD 20742, USA.
Hyuntaek OhDepartment of Chemical and Biomolecular Engineering, 1227C Chemical & Nuclear Engineering Building, University of Maryland, College Park, MD 20742, USA.
Srinivasa R RaghavanDepartment of Chemical and Biomolecular Engineering, 1227C Chemical & Nuclear Engineering Building, University of Maryland, College Park, MD 20742, USA.
Silvia MuroFischell Department of Bioengineering and Institute for Bioscience and Biotechnology Research, 5115 Plant Sciences Building, University of Maryland, College Park, MD 20742, USA.
University of Maryland, College Park · USResearch Institute for Bioscience and Biotechnology · NP

Funding

Targeted replacement of defective lysosomal enzymes in the lung and brainR01HL098416 · NHLBI · UNIV OF MARYLAND, COLLEGE PARK · PI MURO, SILVIA · 2010 to 2020
$3.3M
NHLBI NIH HHS R01 HL098416
6 · The paper itself

Abstract

When administered intravenously, active targeting of drug nanocarriers (NCs) improves biodistribution and endocytosis. Targeting may also improve oral delivery of NCs to treat gastrointestinal (GI) pathologies or for systemic absoption. However, GI instability of targeting moieties compromises this strategy. We explored whether encapsulation of antibody-coated NCs in microcapsules would protect against gastric degradation, providing NCs release and targeting in intestinal conditions. We used nanoparticles coated with antibodies against intercellular adhesion molecule-1 (anti-ICAM) or non-specific IgG. NCs (~160-nm) were encapsulated in ~180-μm microcapsules with an alginate core, in the absence or presence of a chitosan shell. We found >95% NC encapsulation within microcapsules and <10% NC release from microcapsules in storage. There was minimal NC release at gastric pH (<10%) and burst release at intestinal pH (75-85%), slightly attenuated by chitosan. Encapsulated NCs afforded increased protection against degradation (3-4 fold) and increased cell targeting (8-20 fold) after release vs. non-encapsulated NCs. Mouse oral gavage showed that microencapsulation provided 38-65% greater protection of anti-ICAM NCs in the GI tract, 40% lower gastric retention, and 4-9-fold enhanced intestinal biodistribution vs. non-encapsulated NCs. Therefore, microencapsulation of antibody-targeted NCs may enable active targeting strategies to be effective in the context of oral drug delivery.

Indexed as

antibody-coated nanocarrierscontrolled releasegastrointestinal epitheliummicrocapsulesoral drug delivery

Identifiers

PMID27375374
PMCPMC4926773
OpenAlexW2341427075

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.